Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

16 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Abdominal obesity and expression of familial combined hyperlipidemia.
van der Kallen CJ, Voors-Pette C, de Bruin TW. van der Kallen CJ, et al. Obes Res. 2004 Dec;12(12):2054-61. doi: 10.1038/oby.2004.256. Obes Res. 2004. PMID: 15687407
Evidence of insulin resistant lipid metabolism in adipose tissue in familial combined hyperlipidemia, but not type 2 diabetes mellitus.
van der Kallen CJ, Voors-Pette C, Bouwman FG, Keizer HA, Lu JY, van de Hulst RR, Bianchi R, Janssen MJ, Keulen ET, Boeckx WD, Rotter JI, de Bruin TW. van der Kallen CJ, et al. Atherosclerosis. 2002 Oct;164(2):337-46. doi: 10.1016/s0021-9150(02)00109-0. Atherosclerosis. 2002. PMID: 12204806
Familial dyslipidemic hypertension syndrome: familial combined hyperlipidemia, and the role of abdominal fat mass.
Keulen ET, Voors-Pette C, de Bruin TW. Keulen ET, et al. Am J Hypertens. 2001 Apr;14(4 Pt 1):357-63. doi: 10.1016/s0895-7061(00)01280-2. Am J Hypertens. 2001. PMID: 11336182
Excess coronary heart disease in Familial Combined Hyperlipidemia, in relation to genetic factors and central obesity.
Voors-Pette C, de Bruin TW. Voors-Pette C, et al. Atherosclerosis. 2001 Aug;157(2):481-9. doi: 10.1016/s0021-9150(00)00752-8. Atherosclerosis. 2001. PMID: 11472750
Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes.
Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, Charbonnel B, Frederich R, Gallo S, Cosentino F, Shih WJ, Gantz I, Terra SG, Cherney DZI, McGuire DK; VERTIS CV Investigators. Cannon CP, et al. N Engl J Med. 2020 Oct 8;383(15):1425-1435. doi: 10.1056/NEJMoa2004967. Epub 2020 Sep 23. N Engl J Med. 2020. PMID: 32966714
Association Between Vomiting and QT Hysteresis: Data from a TQT Study with the Endothelin A Receptor Antagonist Clazosentan.
Juif PE, Dingemanse J, Voors-Pette C, Ufer M. Juif PE, et al. Among authors: voors pette c. AAPS J. 2020 Aug 3;22(5):103. doi: 10.1208/s12248-020-00485-6. AAPS J. 2020. PMID: 32748293
Population Pharmacokinetic/Pharmacodynamic Modeling of Glenzocimab (ACT017) a Glycoprotein VI Inhibitor of Collagen-Induced Platelet Aggregation.
Renaud L, Lebozec K, Voors-Pette C, Dogterom P, Billiald P, Jandrot Perrus M, Pletan Y, Machacek M. Renaud L, et al. Among authors: voors pette c. J Clin Pharmacol. 2020 Jun 4;60(9):1198-208. doi: 10.1002/jcph.1616. Online ahead of print. J Clin Pharmacol. 2020. PMID: 32500636 Free PMC article.
Effect of Rifampin-Mediated OATP1B1 and OATP1B3 Transporter Inhibition on the Pharmacokinetics of the P2Y12 Receptor Antagonist Selatogrel.
Schilling U, Dingemanse J, Voors-Pette C, Romeijn C, Dogterom P, Ufer M. Schilling U, et al. Among authors: voors pette c. Clin Transl Sci. 2020 Sep;13(5):886-890. doi: 10.1111/cts.12774. Epub 2020 Mar 31. Clin Transl Sci. 2020. PMID: 32166864 Free PMC article.
Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT017, an Antiplatelet GPVI (Glycoprotein VI) Fab.
Voors-Pette C, Lebozec K, Dogterom P, Jullien L, Billiald P, Ferlan P, Renaud L, Favre-Bulle O, Avenard G, Machacek M, Pl├ętan Y, Jandrot-Perrus M. Voors-Pette C, et al. Arterioscler Thromb Vasc Biol. 2019 May;39(5):956-964. doi: 10.1161/ATVBAHA.118.312314. Arterioscler Thromb Vasc Biol. 2019. PMID: 31017822 Clinical Trial.
Influence of Rifampin-Mediated Organic Anion-Transporting Polypeptide 1B1/1B3 Inhibition on the Pharmacokinetics of Clazosentan.
Juif PE, Voors-Pette C, Ufer M, Dogterom P, Dingemanse J. Juif PE, et al. Among authors: voors pette c. Clin Transl Sci. 2019 Sep;12(5):440-444. doi: 10.1111/cts.12639. Epub 2019 May 6. Clin Transl Sci. 2019. PMID: 31004470 Free PMC article. Clinical Trial.
16 results
Jump to page